Opendata, web and dolomites

CUDI SIGNED

Implementation of contrast-ultrasound dispersion imaging for better prostate cancer care

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "CUDI" data sheet

The following table provides information about the project.

Coordinator
TECHNISCHE UNIVERSITEIT EINDHOVEN 

Organization address
address: GROENE LOPER 3
city: EINDHOVEN
postcode: 5612 AE
website: www.tue.nl/en

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 0 €
 EC max contribution 150˙000 € (0%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2019-PoC
 Funding Scheme ERC-POC-LS
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2021-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    TECHNISCHE UNIVERSITEIT EINDHOVEN NL (EINDHOVEN) coordinator 150˙000.00

Map

 Project objective

Prostate cancer (PCa) causes 1/5 of new cancer cases and 1/10 of cancer deaths in western males. Timely diagnosis is crucial to enable effective treatment, but this is hampered by the inadequacy and cost of the available diagnostics based on multiple systematic biopsies, which cause discomfort and health risks because of their invasiveness. Moreover, they fail to provide accurate cancer localization, resulting in either over- or under-treatment. A new diagnostic method is thus needed that is accurate and cost-effective.

Our ambition is to provide patients with accurate diagnosis of PCa by ultrasound imaging. Because ultrasound equipment is affordable and widely available, our method will save lives and cost by enabling noninvasive, timely diagnosis. Over the past years, through a synergic effort of technical and clinical research, we have developed contrast-ultrasound dispersion imaging (CUDI), a revolutionary option to determine cancer location and aggressiveness by detection and characterization of cancer angiogenesis. Our results in 150 patients confirm the accuracy and clinical value of the method.

With this project, we will take CUDI to the next level, establishing the basis for its clinical and commercial translation. To this end, we will realize a commercially-viable software implementation, accounting for user experience, clinical workflow, and regulatory compliance. This project will build on a strong network of international collaborations with key opinion leaders in PCa diagnostics and treatment. We will also account for patient experience via the Dutch Prostate Cancer Association. The establishment of a dedicated start-up driving the valorization activities will provide an additional boost towards the clinical implementation of CUDI.

Our experienced project team combines complementary expertise from academia, industry, and clinic, establishing a solid basis for the valorization and clinical translation of CUDI.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CUDI" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CUDI" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

NanoPD_P (2020)

High throughput multiplexed trace-analyte screening for diagnostics applications

Read More  

TALNET (2020)

Transparent Aluminium Networks

Read More  

Malaria POC (2019)

Ultrasensitive detection of transmissible malaria

Read More